Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine

Biomaterials

Volumn 34, Issue 36, 2013, Pages 9210-9219

  Zhang, Hongbo ^a   Shahbazi, Mohammad Ali ^a   Mäkilä, Ermei M ^a,b   da Silva, Tiago H ^c   Reis, Rui L ^c   Salonen, Jarno J ^b   Hirvonen, Jouni T ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

Cytotoxicity; Diatom; Drug delivery; Mesalamine; Porous silica; Prednisone

Indexed keywords

DIATOM; ENVIRONMENTALLY SAFE; MESALAMINE; PERMEATION ENHANCEMENT; POROUS SILICA; PREDNISONE; PURIFICATION PROCESS; TRANSMISSION ELECTRON;

BIOCHEMISTRY; CELLS; DRUG DELIVERY; DRUG PRODUCTS; MEDICAL APPLICATIONS; MONOLAYERS; PHYTOPLANKTON; SILICA; TRANSMISSION ELECTRON MICROSCOPY;

CYTOTOXICITY;

DIATOM SILICA MICROPARTICLE; MESALAZINE; PREDNISONE; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY;

ALGAE; BACILLARIOPHYTA;

CYTOTOXICITY; DIATOM; DRUG DELIVERY; MESALAMINE; POROUS SILICA; PREDNISONE;

ADMINISTRATION, ORAL; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DELAYED-ACTION PREPARATIONS; DIATOMS; ENTEROCYTES; HCT116 CELLS; HT29 CELLS; HUMANS; MESALAMINE; PARTICLE SIZE; POROSITY; PREDNISONE; SILICON DIOXIDE; STATIC ELECTRICITY;

EID: 84883802197     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.035     Document Type: Article

References (70)

1. Goldberg M., Langer R., Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. JBiomater Sci Polym Ed 2007, 18:241-268.
2. Goldberg M., Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003, 2:289-295.
3. Shahbazi M.A., Santos H.A. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 2013, 14:28-56.
4. Shahbazi M.A., Herranz B., Santos H.A. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter 2012, 2:296-312.
5. Limnell T., Santos H.A., Mäkilä E., Heikkilä T., Salonen J., Murzin D.Y., et al. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods. JPharm Sci 2011, 100:3294-3306.
6. Heikkilä T., Santos H.A., Kumar N., Murzin D.Y., Salonen J., Laaksonen T., et al. Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells. Eur J Pharm Biopharm 2010, 74:483-494.
7. Limnell T., Heikkilä T., Santos H.A., Sistonen S., Hellstén S., Laaksonen T., et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int J Pharm 2011, 416:242-251.
8. Limnell T., Mäkilä E., Heikkilä T., Salonen T., Murzin D.Y., Kumar N., et al. Preparation and characterization of drug formulations of ordered and nonordered mesoporous silica microparticles. Eur J Pharm Sci 2011, 44(S1):S125-S126.
9. Kinnari P., Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm 2011, 414:148-156.
10. Rosenholm J.M., Sahlgren C., Lindén M. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment. Curr Drug Targets 2011, 12:1166-1186.
11. Tang F., Li L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012, 24:1504-1534.
12. Silva T.H., Alves A., Ferreira B.M., Oliveira J.M., Reys L.L., Ferreira R.J.F., et al. Materials of marine origin: a review on polymers and ceramics of biomedical interest. Int Mater Rev 2012, 57:276-306.
13. Gordon R., Losic D., Tiffany M.A., Nagy S.S., Sterrenburg F.A. The glass menagerie: diatoms for novel applications in nanotechnology. Trends Biotechnol 2009, 27:116-127.
14. Losic D., Mitchell J.G., Voelcker N.H. Diatomaceous lessons in nanotechnology and advanced materials. Adv Mater 2009, 21:2947-2958.
15. Losic D., Rosengarten G., Mitchell J.G., Voelcker N.H. Pore architecture of diatom frustules: potential nanostructured membranes for molecular and particle separations. JNanosci Nanotechnol 2006, 6:982-989.
16. Di Caprio G., Coppola G., Stefano L.D., Stefano M.D., Antonucci A., Congestri R., et al. Shedding light on diatom photonics by means of digital holography. JBiophoton 2012, http://dx.doi.org/10.1002/jbio.201200198.
17. Bradbury J. Nature's nanotechnologists: unveiling the secrets of diatoms. PLoS Biol 2004, 2:12.
18. Losic D., Yu Y., Aw M.S., Simovic S., Thierry B., Addai-Mensah J. Surface functionalisation of diatoms with dopamine modified iron-oxide nanoparticles: toward magnetically guided drug microcarriers with biologically derived morphologies. Chem Commun 2010, 46:6323-6325.
19. Aw M.S., Bariana M., Yu Y., Addai-Mensah J., Losic D. Surface-functionalized diatom microcapsules for drug delivery of water-insoluble drugs. JBiomater Appl 2013, 28:163-174.
20. Bye E., Davies R., Griffiths D.M., Gylseth B., Moncrieff C.B. Invitro cytotoxicity and quantitative silica analysis of diatomaceous earth products. Br J Ind Med 1984, 41:228-234.
21. Bariana M., Aw M.S., Kurkuri M., Losic D. Tuning drug loading and release properties of diatom silica microparticles by surface modifications. Int J Pharm 2013, 443:230-241.
22. Zimmerman R.P., Jia Z., Zhu H., Vandjelovic N., Misra H.P., Wang J., et al. Induction of oxidative DNA damage by mesalamine in the presence of copper: a potential mechanism for mesalamine anticancer activity. Toxicology 2011, 280:71-76.
23. Zhou S.Y., Fleisher D., Pao L.H., Li C., Winward B., Zimmermann E.M. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999, 27:479-485.
24. Vogt M., Derendorf H., Krämer J., Junginger H.E., Midha K.K., Shah V.P., et al. Biowaiver monographs for immediate release solid oral dosage forms: prednisone. JPharm Sci 2007, 96:1480-1489.
25. Gilson M.R., Elston L.C., Pruitt C.A. Metastatic Crohn's disease: remission induced by mesalamine and prednisone. JAm Acad Dermatol 1999, 41:476-479.
26. Kichenadasse G., Karapetis C. Abiraterone in metastatic prostate cancer. NEngl J Med 2013, 368:1457-1459.
27. Collnot E.M., Ali H., Lehr C.M. Nano- and microparticulate drug carriers fortargeting of the inflamed intestinal mucosa. JControl Release 2012, 161:235-246.
28. Liu D., Mäkilä E., Zhang H., Herranz B., Kaasalainen M., Kinnari P., et al. Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release. Adv Funct Mater 2013, 23:1893-1902.
29. 2 films prepared by simple and cost effective sol-gel process. Spectrochim Acta A Mol Biomol Spectrosc 2011, 78:695-699.
30. Mladenovska K., Cruaud O., Richomme P., Belamie E., Raicki R.S., Venier-Julienne M.C., et al. 5-ASA loaded chitosan-Ca-alginate microparticles: Preparation and physicochemical characterization. Int J Pharm 2007, 345:59-69.
31. Gill P., Moghadam T.T., Ranjbar B. Differential scanning calorimetry techniques: applications in biology and nanoscience. JBiomol Tech 2010, 21:167-193.
32. Mura C., Nácher A., Merino V., Merino-Sanjuán M., Manconi M., Loy G., et al. Design, characterization and invitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. Colloids Surf B Biointerfaces 2012, 94:199-205.
33. Love S.A., Maurer-Jones M.A., Thompson J.W., Lin Y.S., Haynes C.L. Assessing nanoparticle toxicity. Annu Rev Anal Chem (Palo Alto Calif) 2012, 5:181-205.
34. Bimbo L.M., Peltonen L., Hirvonen J., Santos H.A. Toxicological profile of therapeutic nanodelivery systems. Curr Drug Metab 2012, 13:1068-1086.
35. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Mäkilä E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
36. Santos H.A., Riikonen J., Salonen J., Mäkilä E., Heikkilä T., Laaksonen T., et al. Invitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 2010, 6:2721-2731.
37. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
38. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
39. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
40. Cho E.C., Au L., Zhang Q., Xia Y. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small 2010, 6:517-522.
41. Canton I., Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev 2012, 41:2718-2739.
42. Cho E.C., Xie J., Wurm P.A., Xia Y. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett 2009, 9:1080-1084.
43. Qiu Y., Liu Y., Wang L., Xu L., Bai R., Ji Y., et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials 2010, 31:7606-7619.
44. Fu C., Liu T., Li L., Liu H., Chen D., Tang F. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 2013, 34:2565-2575.
45. Clément L., Zenerino A., Hurel C., Amigoni S., Taffin de Givenchy E., Guittard F., et al. Toxicity assessment of silica nanoparticles, functionalised silica nanoparticles, and HASE-grafted silica nanoparticles. Sci Total Environ 2013, 450-451:120-128.
46. Shahbazi M.-A., Hamidi M., Mäkilä E.M., Zhang H., Almeida P.V., Kaasalainen M., et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013, 34:7776-7789.
47. Invitro toxicity of amorphous silica nanoparticles in human colon carcinoma cells. Nanotoxicology 2013, 7:274-293.
48. Liu D., Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz-Blanco B., et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. JControl Release 2013, 170:268-278.
49. McClements D.J., Li Y. Review of invitro digestion models for rapid screening of emulsion-based systems. Food Funct 2010, 1:32-59.
50. Stolk L.M., Rietbroek R., Wiltink E.H., Tukker J.J. Dissolution profiles of mesalazine formulations invitro. Pharm Weekbl Sci 1990, 12:200-204.
51. Rost M., Quist P.O. Dissolution of USP prednisone calibrator tablets: effects of stirring conditions and particle size distribution. JPharm Biomed Anal 2003, 31:1129-1143.
52. Carter J.D., Zarabadi S.A., Ricca L.R., McNeil A., Valeriano-Marcet J., Vasey F.B., et al. Asafety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis. Clin Rheumatol 2012, 31:1605-1610.
53. Quinteros D.A., Manzo R.H., Allemandi D.A. Design of a colonic delivery system based on cationic polymethacrylate (Eudragit E100)-mesalamine complexes. Drug Deliv 2010, 17:208-213.
54. Actis G.C., Pazienza P., Rosina F. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm Allergy Drug Targets 2008, 7:1-5.
55. Karagozian R., Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag 2007, 3:893-903.
56. Bimbo L.M., Mäkilä E., Laaksonen T., Lehto V.P., Salonen J., Hirvonen J., et al. Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials 2011, 32:2625-2633.
57. Chen X.M., Elisia I., Kitts D.D. Defining conditions for the co-culture of Caco-2 and HT29-MTX cells using Taguchi design. JPharmacol Toxicol Methods 2010, 61:334-342.
58. Mahler G.J., Shuler M.L., Glahn R.P. Characterization of Caco-2 and HT29-MTX cocultures in an invitro digestion/cell culture model used to predict iron bioavailability. JNutr Biochem 2009, 20:494-502.
59. Woitiski C.B., Sarmento B., Carvalho R.A., Neufeld R.J., Veiga F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 2011, 412:123-131.
60. Fonte P., Andrade F., Araújo F., Andrade C., Neves Jd, Sarmento B. Chapterfifteen-chitosan-coated solid lipid nanoparticles for insulin delivery. Methods in enzymology 2012, 295-314. Academic Press. D. Nejat (Ed.).
61. Sonaje K., Lin K.-J., Wang J.-J., Mi F.-L., Chen C.-T., Juang J.-H., et al. Self-assembled pH-Sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv Funct Mater 2010, 20:3695-3700.
62. Chen M.C., Mi F.L., Liao Z.X., Hsiao C.W., Sonaje K., Chung M.F., et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013, 65:865-879.
63. Su F.Y., Lin K.J., Sonaje K., Wey S.P., Yen T.C., Ho Y.C., et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 2012, 33:2801-2811.
64. Sonaje K., Chuang E.Y., Lin K.J., Yen T.C., Su F.Y., Tseng M.T., et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012, 9:1271-1279.
65. Guo X., Rao J.N., Liu L., Zou T.T., Turner D.J., Bass B.L., et al. Regulation of adherens junctions and epithelial paracellular permeability: a novel function for polyamines. Am J Physiol Cell Physiol 2003, 285:9.
66. Banan A., Zhang L.J., Shaikh M., Fields J.Z., Choudhary S., Forsyth C.B., et al. theta Isoform of protein kinase C alters barrier function in intestinal epithelium through modulation of distinct claudin isotypes: a novel mechanism for regulation of permeability. JPharmacol Exp Ther 2005, 313:962-982.
67. Yeh T.H., Hsu L.W., Tseng M.T., Lee P.L., Sonjae K., Ho Y.C., et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011, 32:6164-6173.
68. Ginski M.J., Polli J.E. Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system. Int J Pharm 1999, 177:117-125.
69. Sandborn W.J., Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003, 17:29-42.
70. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.